A core outcome set for studies of gestational diabetes mellitus prevention and treatment.


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
06 2020
Historique:
received: 17 12 2019
accepted: 18 02 2020
pubmed: 21 3 2020
medline: 30 9 2021
entrez: 21 3 2020
Statut: ppublish

Résumé

The aim of this systematic review was to develop core outcome sets (COSs) for trials evaluating interventions for the prevention or treatment of gestational diabetes mellitus (GDM). We identified previously reported outcomes through a systematic review of the literature. These outcomes were presented to key stakeholders (including patient representatives, researchers and clinicians) for prioritisation using a three-round, e-Delphi study. A priori consensus criteria informed which outcomes were brought forward for discussion at a face-to-face consensus meeting where the COS was finalised. Our review identified 74 GDM prevention and 116 GDM treatment outcomes, which were presented to stakeholders in round 1 of the e-Delphi study. Round 1 was completed by 173 stakeholders, 70% (121/173) of whom went on to complete round 2; 84% (102/121) of round 2 responders completed round 3. Twenty-two GDM prevention outcomes and 30 GDM treatment outcomes were discussed at the consensus meeting. Owing to significant overlap between included prevention and treatment outcomes, consensus meeting stakeholders agreed to develop a single prevention/treatment COS. Fourteen outcomes were included in the final COS. These consisted of six maternal outcomes (GDM diagnosis, adherence to the intervention, hypertensive disorders of pregnancy, requirement and type of pharmacological therapy for hyperglycaemia, gestational weight gain and mode of birth) and eight neonatal outcomes (birthweight, large for gestational age, small for gestational age, gestational age at birth, preterm birth, neonatal hypoglycaemia, neonatal death and stillbirth). This COS will enable future GDM prevention and treatment trials to measure similar outcomes that matter to stakeholders and facilitate comparison and combination of these studies. This study was registered prospectively with the Core Outcome Measures in Effectiveness Trials (COMET) database: http://www.comet-initiative.org/studies/details/686/.

Identifiants

pubmed: 32193573
doi: 10.1007/s00125-020-05123-6
pii: 10.1007/s00125-020-05123-6
pmc: PMC7228989
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1120-1127

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK036836
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK104649
Pays : United States

Références

Diabetes Care. 2016 Jan;39(1):75-81
pubmed: 26645084
PLoS Med. 2017 Nov 16;14(11):e1002447
pubmed: 29145404
Diabetologia. 2019 Nov;62(11):2007-2016
pubmed: 31273408
Am J Obstet Gynecol. 2019 Oct;221(4):339.e1-339.e10
pubmed: 31152710
Am J Obstet Gynecol. 2010 Mar;202(3):255.e1-7
pubmed: 20207245
Diabet Med. 2010 Apr;27(4):436-41
pubmed: 20536516
JAMA. 2008 Dec 24;300(24):2886-97
pubmed: 19109117
J Womens Health (Larchmt). 2012 Sep;21(9):925-32
pubmed: 22747422
Trials. 2013 Mar 12;14:70
pubmed: 23497540
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Diabetes Metab Res Rev. 2015 Oct;31(7):680-90
pubmed: 25663190
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
Aust N Z J Obstet Gynaecol. 2016 Feb;56(1):113-6
pubmed: 26757351
J Pediatr. 2010 May;156(5):719-23, 723.e1
pubmed: 20106489
Diabetes Care. 2019 Mar;42(3):381-392
pubmed: 30617141
Diabetologia. 2017 Jul;60(7):1190-1196
pubmed: 28409213
N Engl J Med. 2008 May 8;358(19):1991-2002
pubmed: 18463375
Trials. 2012 Aug 06;13:132
pubmed: 22867278
Am J Obstet Gynecol. 2014 Dec;211(6):575-6
pubmed: 25459559
BMJ Open. 2019 Nov 14;9(11):e030574
pubmed: 31727651
Lancet. 2009 May 23;373(9677):1773-9
pubmed: 19465232
Nutr Metab Cardiovasc Dis. 2019 Feb;29(2):115-126
pubmed: 30642790
Diabetes Res Clin Pract. 2018 Apr;138:271-281
pubmed: 29496507
Cochrane Database Syst Rev. 2017 Jan 25;1:CD011967
pubmed: 28120427
Diabetologia. 2011 Jul;54(7):1670-5
pubmed: 21494772

Auteurs

Aoife M Egan (AM)

Division of Endocrinology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA. egan.aoife@mayo.edu.

Delia Bogdanet (D)

School of Medicine, National University of Ireland Galway, Galway, Ireland.

Tomás P Griffin (TP)

School of Medicine, National University of Ireland Galway, Galway, Ireland.
Department of Endocrinology, St Vincent's University Hospital, Dublin, Ireland.

Oratile Kgosidialwa (O)

School of Medicine, National University of Ireland Galway, Galway, Ireland.

Mila Cervar-Zivkovic (M)

Division of Obstetrics, Medizinische Universitat Graz, Graz, Austria.

Eugene Dempsey (E)

INFANT Centre and Department of Paediatrics & Child Health, University College Cork, Cork, Ireland.

John Allotey (J)

Barts Research Centre for Women's Health (BARC), Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Fernanda Alvarado (F)

Mother Infant Research Institute, Tufts Medical Center, Boston, MA, USA.

Cheril Clarson (C)

Department of Pediatrics, University of Western Ontario, London, ON, Canada.
Lawson Health Research Institute, London, ON, Canada.

Shamil D Cooray (SD)

Barts Research Centre for Women's Health (BARC), Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Diabetes and Vascular Medicine Unit, Monash Health, Melbourne, VIC, Australia.
Monash Centre for Health Research and Implementation, Monash University, Melbourne, VIC, Australia.

Harold W de Valk (HW)

Department of Internal Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands.

Sander Galjaard (S)

Department of Obstetrics and Gynaecology, Division of Obstetrics and Prenatal Medicine, Erasmus MC, University Medical Centre Rotterdam, 's-Gravendijkwal 230, 3015 CE, Rotterdam, the Netherlands. s.galjaard@erasmusmc.nl.

Mary R Loeken (MR)

Section of Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.

Michael J A Maresh (MJA)

Department of Obstetrics, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Angela Napoli (A)

Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, Sapienza, University of Rome, Rome, Italy.

Paula M O'Shea (PM)

School of Medicine, National University of Ireland Galway, Galway, Ireland.

Ewa Wender-Ozegowska (E)

Department of Reproduction, Poznan University of Medical Sciences, Poznan, Poland.

Mireille N M van Poppel (MNM)

Institute of Sport Science, University of Graz, Graz, Austria.

Shakila Thangaratinam (S)

Barts Research Centre for Women's Health (BARC), Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

Caroline Crowther (C)

Liggins Institute, The University of Auckland, Auckland, New Zealand.

Linda M Biesty (LM)

School of Nursing and Midwifery, National University of Ireland Galway, Galway, Ireland.
HRB-Trials Methodology Research Network, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland.

Declan Devane (D)

INFANT Centre and Department of Paediatrics & Child Health, University College Cork, Cork, Ireland.
School of Nursing and Midwifery, National University of Ireland Galway, Galway, Ireland.
HRB-Trials Methodology Research Network, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland.

Fidelma P Dunne (FP)

School of Medicine, National University of Ireland Galway, Galway, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH